Accumulating studies have demonstrated that acquired resistance to chemotherapeutic agents such as platinum, EGFR-TK inhibitors, and ALK inhibitors is associated with increased PD-L1 in cancer cells [10–12, 35, 36]. Here, ALK is linked to cancer.